港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

荃信生物-B

20.460

-0.580-2.76%

成交量：22.18万

成交额：452.08万

市值：46.24亿

市盈率：-12.23

高：21.520

开：21.040

低：19.900

收：21.040

52周最高：36.500

52周最低：5.950

股本：2.26亿

香港流通股本：2.26亿

量比：0.35

换手率：0.10%

股息：- -

股息率：- -

每股收益(LYR):-1.672

净资产收益率：-68.26%

总资产收益率：-10.67%

市净率：18.68

市盈率(LYR):-12.23

市销率: 13.20

数据加载中...

总览公司新闻资讯公告

荃信生物-B(02509)11月17日斥资71.19万港元回购3.46万股

每日卖空追踪 | 荃信生物-B 11月14日卖空量成交2万股，卖空比例为3.26%

荃信生物-B - QX027n注射剂获得NMPA药品审评中心的两项临床试验批准

荃信生物-B(02509)：长效双抗QX027N获得两项临床试验默示许可

港股异动 | 荃信生物-B(02509)涨超10% 拟重续QX001S框架协议年度上限公司自免双抗价值持续兑现

智通港股回购统计|11月12日

荃信生物-B(02509)11月11日耗资约99.88万港元回购5.22万股

透视81家创新药企三季报：亏损收窄医保放量BD增长释放什么信号？

疾病专题报告(四)：双抗在自免领域潜力大

荃信生物-B11月10日遭主力抛售62.4万元

中邮证券-医药生物行业周报：自免口服药物市场存在供需错配，关注NME带来的积极转变-251110

智通港股回购统计|11月10日

BD神话带不动创新药了？

荃信生物-B于11月7日斥资607.13万港元回购30.42万股

荃信生物-B(02509.HK)11月7日耗资607.1万港元回购30.4万股

荃信生物-B(02509)11月6日斥资199.61万港元回购8.92万股

药闻医讯 | 国家药监局药审中心关于发布《创新药研发中涉及适老化设计时的一般原则及考虑要点（试行）》的通告（2025年第45号）

巨头重金入场

药视声Medispace

荃信生物-B盘中异动早盘快速下挫5.66%

港股异动 | 荃信生物-B(02509)盘中涨超11% 旗下QX031N授权罗氏机构称本次交易具备一定稀缺性

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02509/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02509","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02509\",,,,,undefined,":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"荃信生物-B","latestPrice":20.46,"timestamp":1763366895006,"preClose":21.04,"halted":0,"volume":221800,"delay":0,"floatShares":225999999,"shares":225999999,"eps":-1.6725001111197477,"marketStatus":"未开盘","change":-0.58,"latestTime":"11-17 16:08:15","open":21.04,"high":21.52,"low":19.9,"amount":4520830,"amplitude":0.076996,"askPrice":20.46,"askSize":1000,"bidPrice":20.44,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.9444881499319833,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":0,"adr":0,"listingDate":1710864000000,"exchange":"SEHK","adjPreClose":21.04,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":0.345273,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02509\",,,,,undefined,":{"symbol":"02509","floatShares":225999999,"roa":"-10.67%","roe":"-68.26%","lyrEps":-1.6725,"volumeRatio":0.345273,"shares":225999999,"dividePrice":0,"high":21.52,"amplitude":0.076996,"preClose":21.04,"low":19.9,"week52Low":5.95,"pbRate":"18.68","psRate":"13.20","week52High":36.5,"institutionHeld":0,"latestPrice":20.46,"eps":-1.6725001111197477,"divideRate":0,"volume":221800,"delay":0,"ttmEps":-0.9444881499319833,"open":21.04,"prevYearClose":7.38,"prevWeekClose":21.04,"prevMonthClose":21.78,"prevQuarterClose":34.88,"fiveDayClose":19.23,"twentyDayClose":28.58,"sixtyDayClose":25.26},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02509\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"02509","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743125400000,"name":null,"time":"盘后","dateTimestamp":1743091200000,"actualEps":null},{"date":"2024-08-15","symbol":"02509","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1723685400000,"name":null,"time":"","dateTimestamp":1723651200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02509\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02509\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02509\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02509","date":"2025-11-14","current":-21.669289,"percent":0.137592,"low":-38.274716,"twenty":-12.458841,"median":-9.113568,"eighty":-5.155799,"high":-3.10587,"avg":-11.166916,"sd":8.268519,"marketCap":4764920384},"quantilePoints":[{"date":"2024-03-22","current":-9.005941,"twenty":-9.920087,"median":-9.005941,"eighty":-8.797979,"marketCap":4652400020},{"date":"2024-03-28","current":-9.367246,"twenty":-9.484937,"median":-9.005941,"eighty":-8.416995,"marketCap":4821843660},{"date":"2024-04-05","current":-8.872714,"twenty":-9.396669,"median":-8.977885,"eighty":-8.598751,"marketCap":4565907160},{"date":"2024-04-12","current":-9.165919,"twenty":-9.386227,"median":-9.126184,"eighty":-8.830039,"marketCap":4719469060},{"date":"2024-04-19","current":-9.074252,"twenty":-9.304842,"median":-9.125412,"eighty":-8.934406,"marketCap":4668281760},{"date":"2024-04-26","current":-9.882424,"twenty":-9.513374,"median":-9.232059,"eighty":-8.994719,"marketCap":5077780160},{"date":"2024-05-03","current":-10.208268,"twenty":-9.517937,"median":-9.234052,"eighty":-9.046928,"marketCap":5241579520},{"date":"2024-05-10","current":-10.950727,"twenty":-10.058378,"median":-9.328243,"eighty":-9.081967,"marketCap":6018140360},{"date":"2024-05-17","current":-11.513141,"twenty":-10.522167,"median":-9.424295,"eighty":-9.09098,"marketCap":6317937020},{"date":"2024-05-24","current":-11.397533,"twenty":-11.287555,"median":-9.513128,"eighty":-9.098359,"marketCap":6240211960},{"date":"2024-05-31","current":-10.960491,"twenty":-11.380385,"median":-9.702863,"eighty":-9.110289,"marketCap":6007036780},{"date":"2024-06-07","current":-9.736726,"twenty":-11.329803,"median":-9.882424,"eighty":-9.125257,"marketCap":5329718400},{"date":"2024-06-14","current":-9.786262,"twenty":-11.239813,"median":-9.736726,"eighty":-9.134131,"marketCap":5351925560},{"date":"2024-06-21","current":-11.51586,"twenty":-11.394726,"median":-9.834343,"eighty":-9.179147,"marketCap":6284626280},{"date":"2024-06-28","current":-7.449742,"twenty":-11.394726,"median":-9.882424,"eighty":-9.134131,"marketCap":4063910280},{"date":"2024-07-05","current":-8.013266,"twenty":-11.3835,"median":-9.736726,"eighty":-9.096784,"marketCap":4370369088},{"date":"2024-07-12","current":-8.782148,"twenty":-11.375713,"median":-9.612459,"eighty":-8.973485,"marketCap":4796746560},{"date":"2024-07-19","current":-8.033889,"twenty":-11.260937,"median":-9.536435,"eighty":-8.759388,"marketCap":4388134816},{"date":"2024-07-26","current":-8.627957,"twenty":-11.24224,"median":-9.513744,"eighty":-8.627957,"marketCap":4730125080},{"date":"2024-08-02","current":-9.119354,"twenty":-11.155317,"median":-9.51436,"eighty":-8.659337,"marketCap":4996611000},{"date":"2024-08-09","current":-9.602516,"twenty":-11.096166,"median":-9.502501,"eighty":-8.759388,"marketCap":5296407660},{"date":"2024-08-16","current":-9.659156,"twenty":-11.082764,"median":-9.523303,"eighty":-8.782148,"marketCap":5329718400},{"date":"2024-08-23","current":-11.457751,"twenty":-11.24224,"median":-9.560506,"eighty":-8.785621,"marketCap":5274200500},{"date":"2024-08-30","current":-11.261539,"twenty":-11.260937,"median":-9.602516,"eighty":-8.853804,"marketCap":5218682600},{"date":"2024-09-06","current":-12.381731,"twenty":-11.301814,"median":-9.616314,"eighty":-8.872714,"marketCap":5740550860},{"date":"2024-09-13","current":-12.966504,"twenty":-11.41285,"median":-9.666597,"eighty":-8.919616,"marketCap":5995933200},{"date":"2024-09-20","current":-13.175636,"twenty":-11.495182,"median":-9.727036,"eighty":-8.943786,"marketCap":6129176160},{"date":"2024-09-27","current":-11.412309,"twenty":-11.503472,"median":-9.834343,"eighty":-8.968754,"marketCap":5340821980},{"date":"2024-10-04","current":-10.630177,"twenty":-11.500266,"median":-9.955419,"eighty":-8.992959,"marketCap":4952196680},{"date":"2024-10-10","current":-9.640046,"twenty":-11.496891,"median":-9.984689,"eighty":-9.012278,"marketCap":4463639160},{"date":"2024-10-18","current":-7.823087,"twenty":-11.483911,"median":-9.882424,"eighty":-8.891475,"marketCap":3602001352},{"date":"2024-10-25","current":-6.637022,"twenty":-11.464072,"median":-9.731881,"eighty":-8.768492,"marketCap":3055705216},{"date":"2024-11-01","current":-6.266219,"twenty":-11.439791,"median":-9.666597,"eighty":-8.552796,"marketCap":2886930800},{"date":"2024-11-08","current":-6.11978,"twenty":-11.412634,"median":-9.628889,"eighty":-8.354641,"marketCap":2798102160},{"date":"2024-11-15","current":-4.903744,"twenty":-11.406399,"median":-9.610023,"eighty":-8.146037,"marketCap":2225157432},{"date":"2024-11-22","current":-4.446271,"twenty":-11.39192,"median":-9.574881,"eighty":-7.917147,"marketCap":2016410128},{"date":"2024-11-29","current":-5.262129,"twenty":-11.380385,"median":-9.536435,"eighty":-7.700796,"marketCap":2385048984},{"date":"2024-12-06","current":-5.795133,"twenty":-11.346153,"median":-9.513744,"eighty":-7.24659,"marketCap":2620444880},{"date":"2024-12-13","current":-4.23234,"twenty":-11.292835,"median":-9.462151,"eighty":-6.614509,"marketCap":1912036476},{"date":"2024-12-20","current":-3.65763,"twenty":-11.272236,"median":-9.353096,"eighty":-6.423955,"marketCap":1643329840},{"date":"2024-12-27","current":-3.704989,"twenty":-11.261539,"median":-9.289241,"eighty":-6.377951,"marketCap":1663316284},{"date":"2025-01-03","current":-3.459219,"twenty":-11.261057,"median":-9.234052,"eighty":-6.353973,"marketCap":1554501200},{"date":"2025-01-10","current":-3.422771,"twenty":-11.250301,"median":-9.146052,"eighty":-6.232964,"marketCap":1532294040},{"date":"2025-01-17","current":-3.325837,"twenty":-11.24332,"median":-9.119354,"eighty":-5.607796,"marketCap":1490100436},{"date":"2025-01-24","current":-3.940539,"twenty":-11.188065,"median":-9.092192,"eighty":-5.378133,"marketCap":1776572800},{"date":"2025-01-28","current":-4.706176,"twenty":-11.17068,"median":-9.087355,"eighty":-5.266211,"marketCap":2131887360},{"date":"2025-02-07","current":-3.301677,"twenty":-11.154739,"median":-9.066381,"eighty":-4.958001,"marketCap":1487879720},{"date":"2025-02-14","current":-3.418254,"twenty":-11.143754,"median":-8.989713,"eighty":-4.539173,"marketCap":1536735472},{"date":"2025-02-21","current":-3.43891,"twenty":-11.106485,"median":-8.919616,"eighty":-4.354459,"marketCap":1554501200},{"date":"2025-02-28","current":-3.351703,"twenty":-11.093486,"median":-8.819713,"eighty":-4.122814,"marketCap":1510086880},{"date":"2025-03-07","current":-3.387392,"twenty":-11.071174,"median":-8.759388,"eighty":-3.975573,"marketCap":1532294040},{"date":"2025-03-14","current":-5.398225,"twenty":-11.023325,"median":-8.622598,"eighty":-3.975573,"marketCap":2442787600},{"date":"2025-03-21","current":-4.408646,"twenty":-11.005989,"median":-8.475358,"eighty":-3.996365,"marketCap":1994202968},{"date":"2025-03-28","current":-4.427424,"twenty":-10.958538,"median":-8.354936,"eighty":-4.069456,"marketCap":1998644400},{"date":"2025-04-03","current":-5.532239,"twenty":-10.950727,"median":-8.251895,"eighty":-4.071454,"marketCap":1987540820},{"date":"2025-04-11","current":-5.176788,"twenty":-10.949179,"median":-8.134698,"eighty":-4.113712,"marketCap":1843194280},{"date":"2025-04-17","current":-5.605956,"twenty":-10.931954,"median":-8.013266,"eighty":-4.15012,"marketCap":1998644400},{"date":"2025-04-25","current":-6.813611,"twenty":-10.860673,"median":-7.855635,"eighty":-4.203093,"marketCap":2433904736},{"date":"2025-05-02","current":-6.97286,"twenty":-10.741685,"median":-7.823087,"eighty":-4.240312,"marketCap":2496084784},{"date":"2025-05-09","current":-6.850326,"twenty":-10.62989,"median":-7.688151,"eighty":-4.256936,"marketCap":2469436192},{"date":"2025-05-16","current":-6.660384,"twenty":-10.625613,"median":-7.362552,"eighty":-4.28571,"marketCap":2420580440},{"date":"2025-05-23","current":-6.920763,"twenty":-10.596701,"median":-7.188701,"eighty":-4.327055,"marketCap":2522733376},{"date":"2025-05-30","current":-6.975387,"twenty":-10.531077,"median":-7.035719,"eighty":-4.335168,"marketCap":2553823400},{"date":"2025-06-06","current":-8.954176,"twenty":-10.530643,"median":-7.056435,"eighty":-4.354459,"marketCap":3286659680},{"date":"2025-06-13","current":-10.1118,"twenty":-10.525842,"median":-7.245424,"eighty":-4.362058,"marketCap":3713037152},{"date":"2025-06-20","current":-9.295434,"twenty":-10.49786,"median":-7.449742,"eighty":-4.377592,"marketCap":3406578344},{"date":"2025-06-27","current":-9.088195,"twenty":-10.44408,"median":-7.654473,"eighty":-4.399074,"marketCap":3339956864},{"date":"2025-07-04","current":-9.256954,"twenty":-10.441448,"median":-7.771425,"eighty":-4.408646,"marketCap":3402136912},{"date":"2025-07-11","current":-9.278386,"twenty":-10.438605,"median":-7.855635,"eighty":-4.408983,"marketCap":3406578344},{"date":"2025-07-18","current":-10.375245,"twenty":-10.375245,"median":-8.023578,"eighty":-4.415927,"marketCap":3806307224},{"date":"2025-07-25","current":-11.242346,"twenty":-10.444738,"median":-8.163045,"eighty":-4.427424,"marketCap":4139414624},{"date":"2025-08-01","current":-12.956889,"twenty":-10.531115,"median":-8.317696,"eighty":-4.446271,"marketCap":4741228660},{"date":"2025-08-08","current":-12.531071,"twenty":-10.816023,"median":-8.356409,"eighty":-4.497422,"marketCap":4596882120},{"date":"2025-08-15","current":-13.616918,"twenty":-10.950727,"median":-8.486422,"eighty":-4.706176,"marketCap":4987728136},{"date":"2025-08-22","current":-28.922954,"twenty":-11.024815,"median":-8.611071,"eighty":-4.860396,"marketCap":6035906088},{"date":"2025-08-29","current":-26.076607,"twenty":-11.152426,"median":-8.643647,"eighty":-4.89511,"marketCap":5467884128},{"date":"2025-09-05","current":-27.424941,"twenty":-11.24224,"median":-8.759388,"eighty":-4.895913,"marketCap":5744911480},{"date":"2025-09-12","current":-33.976118,"twenty":-11.261539,"median":-8.783884,"eighty":-4.903744,"marketCap":7130048240},{"date":"2025-09-19","current":-32.137812,"twenty":-11.3835,"median":-8.872714,"eighty":-4.920955,"marketCap":6739485088},{"date":"2025-09-26","current":-31.917438,"twenty":-11.446602,"median":-8.942813,"eighty":-4.93749,"marketCap":6675905040},{"date":"2025-10-03","current":-36.693474,"twenty":-11.494681,"median":-8.957754,"eighty":-4.939756,"marketCap":7693185808},{"date":"2025-10-10","current":-31.866218,"twenty":-11.50418,"median":-8.989713,"eighty":-4.971797,"marketCap":6671363608},{"date":"2025-10-17","current":-31.02267,"twenty":-11.536491,"median":-9.052042,"eighty":-5.060821,"marketCap":6489706328},{"date":"2025-10-24","current":-25.824743,"twenty":-11.67702,"median":-9.080681,"eighty":-5.119056,"marketCap":5404304080},{"date":"2025-10-31","current":-23.597698,"twenty":-11.854109,"median":-9.087898,"eighty":-5.129572,"marketCap":4945619448},{"date":"2025-11-07","current":-20.869587,"twenty":-12.197299,"median":-9.096784,"eighty":-5.138538,"marketCap":4371128300},{"date":"2025-11-14","current":-22.685433,"twenty":-12.458841,"median":-9.113568,"eighty":-5.155799,"marketCap":4764920384}],"updateTime":1763390323988},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02509\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584626401","title":"荃信生物-B(02509)11月17日斥资71.19万港元回购3.46万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584626401","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584626401?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 21:34","pubTimestamp":1763386465,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，于2025年11月17日，该公司斥资71.19万港元回购3.46万股股份，每股回购价格为20.16-20.72港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2583508834","title":"每日卖空追踪 | 荃信生物-B 11月14日卖空量成交2万股，卖空比例为3.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583508834","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583508834?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 16:30","pubTimestamp":1763109032,"startTime":"0","endTime":"0","summary":"荃信生物-B北京时间11月14日，涨3.34%，卖空量成交2万股，较上一交易日增加100%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111416405395041ee9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111416405395041ee9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"1104120597","title":"荃信生物-B - QX027n注射剂获得NMPA药品审评中心的两项临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1104120597","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104120597?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 22:16","pubTimestamp":1763043373,"startTime":"0","endTime":"0","summary":"荃信生物-B - QX027n注射剂获得NMPA药品审评中心的两项临床试验批准","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2583596530","title":"荃信生物-B(02509)：长效双抗QX027N获得两项临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2583596530","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583596530?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 22:14","pubTimestamp":1763043269,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，公司自主研发的长效双抗QX027N注射液获得国家药品监督管理局药品审评中心的临床试验默示许可(受理号： CXSL2500757，CXSL2500758)，拟用于治疗哮喘及特应性皮炎。该候选药物的临床许可标志着公司在自免及过敏疾病领域的创新双抗矩阵正式迈入临床阶段。QX027N是公司双特异性抗体研发的重要成果，意味着公司在呼吸和皮肤两大疾病领域的协同布局取得进一步进展。面对全球数亿哮喘与特应性皮炎患者亟待解决的临床需求，公司将持续推进创新疗法的研发与临床转化，为患者提供更高效、更安全及更便利的治疗选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2583360475","title":"港股异动 | 荃信生物-B(02509)涨超10% 拟重续QX001S框架协议年度上限 公司自免双抗价值持续兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2583360475","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583360475?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 11:07","pubTimestamp":1763003233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荃信生物-B涨超10%，截至发稿，涨10.11%，报20.92港元，成交额1060.24万港元。消息面上，荃信生物日前公告称，董事会已考虑赛乐信商业化后的业务需要，并建议根据QX001S框架协议的条款为2026年至2028年三个财政年度的持续关连交易重续新年度上限。值得一提的是，荃信生物此前宣布与罗氏就其自主研发的长效自免双抗QX031N达成全球独家合作与许可协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2582314897","title":"智通港股回购统计|11月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=2582314897","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582314897?lang=zh_cn&edition=fundamental","pubTime":"2025-11-12 09:10","pubTimestamp":1762909802,"startTime":"0","endTime":"0","summary":"其中，回购金额最大的为中国飞鹤，回购数量1200.00 万，回购金额5348.00 万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01586","BK1222","02869","01167","BK1619","BK1519","06826","02039","00386","BK1575","01681","02282","BK1155","LU0821914370.USD","03798","01588","09959","00777","02509","LU0348805143.USD","02416","BK1160","02142","00418","06186","00103","BK1518","00732","LU2097828557.USD","LU0828237940.HKD","LU0326950275.SGD","00909","BK1528","01066","08188","BK1170","02486","00947","02469","01919","02598","BK1585","00799","02251","06868","02171","00383","02038","02299","BK1237"],"gpt_icon":0},{"id":"2582643313","title":"荃信生物-B(02509)11月11日耗资约99.88万港元回购5.22万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582643313","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582643313?lang=zh_cn&edition=fundamental","pubTime":"2025-11-11 21:34","pubTimestamp":1762868064,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)公布，2025年11月11日耗资约99.88万港元回购5.22万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2582357420","title":"透视81家创新药企三季报：亏损收窄医保放量BD增长释放什么信号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2582357420","media":"投资时报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582357420?lang=zh_cn&edition=fundamental","pubTime":"2025-11-11 15:35","pubTimestamp":1762846544,"startTime":"0","endTime":"0","summary":"整体来看，81家A股创新药上市公司归母净利润实现同比增长，增幅达13.84%。数据显示，近年来，中国创新药企业国际授权合作数量不断增加。截至10月21日，2025年中国创新药对外许可交易115起，总金额1012.4亿美元，远超2024年全年519亿美元。11月3日，为期五天的2025年国家医保谈判收官，今年的国家医保谈判，在延续医保目录常规调整机制的基础上，首次引入商保创新药目录新机制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111153610a6f15fdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111153610a6f15fdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03692","09887","BK1574","09969","06978","01276","BK1161","02509"],"gpt_icon":0},{"id":"2582365617","title":"疾病专题报告(四)：双抗在自免领域潜力大","url":"https://stock-news.laohu8.com/highlight/detail?id=2582365617","media":"财通证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582365617?lang=zh_cn&edition=fundamental","pubTime":"2025-11-11 00:00","pubTimestamp":1762790400,"startTime":"0","endTime":"0","summary":"由于TCE 的疗效主要来自B 细胞清除能力强弱，因此根据自免疾病特点及B 细胞表面抗原表达周期，我们认为CD3 与CD19/BCMA的组合将是潜力较大的产品，但同时B 细胞清除能力越强，意味着免疫能力越弱，因此对于该类产品需要关注感染及低丙种球蛋白血症的不良反应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111195133a6f1ef51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111195133a6f1ef51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2582265398","title":"荃信生物-B11月10日遭主力抛售62.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582265398","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582265398?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 16:16","pubTimestamp":1762762565,"startTime":"0","endTime":"0","summary":"11月10日, 荃信生物-B股价跌0.10%，报收19.23元，成交金额1547.2万元，换手率0.36%，振幅8.00%，量比0.99。荃信生物-B今日主力资金净流出62.4万元，上一交易日主力净流出33.2万元。该股近5个交易日下跌17.75%，主力资金累计净流出105.0万元；近20日主力资金累计净流入769.3万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110162344a6eef8f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110162344a6eef8f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2582846287","title":"中邮证券-医药生物行业周报：自免口服药物市场存在供需错配，关注NME带来的积极转变-251110","url":"https://stock-news.laohu8.com/highlight/detail?id=2582846287","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582846287?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 12:02","pubTimestamp":1762747320,"startTime":"0","endTime":"0","summary":"本周主题本周我们探讨自免领域的口服药物市场价值。自免药物的口服需求庞大，现有疗法存在供需错配。参考NatureReviews，2023年银屑病整体市场为270亿美金，其中口服药物为25亿美金，仅占9%。药物市场主要由IL-23、IL-17和TNF等生物类抑制剂占据。从需求端来看，75%接受注射疗法的病人存在转换为口服的意愿。恒生医疗保健指数下跌2.39%，板块整体跑输恒生指数3.68pct。在恒生12个一级子行业中，医疗保健行业周涨跌幅排名为第12位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110125601a49646b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110125601a49646b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","IE00B5MMRT66.SGD","LU0348783233.USD","LU0417516738.SGD","LU0417516571.SGD","LU0561508036.HKD","09887","BK1161","LU0348766576.USD","03759","LU1720050803.USD","LU0417516902.SGD","LU2488822045.USD","02509","06978","BK1574","LU0348827113.USD","LU2399975544.HKD","LU1794554557.SGD","LU2476274308.USD","LU0348825331.USD","LU0348767384.USD","IE00B543WZ88.USD","LU0348735423.USD","LU0634319403.HKD","LU0348784397.USD","09606","IE00BPRC5H50.USD","02157","01276","LU2778985437.USD","LU0540923850.HKD","LU2476274720.SGD","LU1961090484.USD"],"gpt_icon":0},{"id":"2582812849","title":"智通港股回购统计|11月10日","url":"https://stock-news.laohu8.com/highlight/detail?id=2582812849","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582812849?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 09:10","pubTimestamp":1762737002,"startTime":"0","endTime":"0","summary":"其中，回购金额最大的为中国飞鹤，回购数量600.00 万，回购金额2608.34 万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00103","06186","02886","08188","LU0228659784.USD","08128","02120","02319","09987","01588","00418","01681","SG9999011746.SGD","02509","LU0106959298.USD","LU0385154629.USD","00777","01586","02299","01167","02142","02598","00799","02039","02486","00909","00732","00366","LU1023057109.AUD","09966","02171","01919","09885","02190","06826","02057","06868","01066","00947","LU1235295612.USD","00386","01358","02343","02018","02282","02416","02469","02869","09959","LU2097828557.USD"],"gpt_icon":0},{"id":"2582816482","title":"BD神话带不动创新药了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2582816482","media":"药闻社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582816482?lang=zh_cn&edition=fundamental","pubTime":"2025-11-09 23:12","pubTimestamp":1762701136,"startTime":"0","endTime":"0","summary":"总额高达114亿美元，刷新中国药企BD交易金额记录。MNC倾向靠“堆量”逻辑大批购买中国早期资产，但二级市场流通的钱一共就那么多，投资者在大量雷同交易中渐渐会出现选择犹豫或“祛魅”心态，最终出现“BD带不动创新药”的现象；裂痕已经初见端倪。而目前中国创新药企业交易的BD管线，大部分都属于后面一种情况。2019年，武田以约620亿美元收购Shire，使其背负了巨额债务。和传统BD相比，Co-Co中里程碑付款占总款比例较高，这也","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251109231734a494f4b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251109231734a494f4b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","02509","BK1191","BK1589","06978","BK1161","03692","02616"],"gpt_icon":0},{"id":"2582898108","title":"荃信生物-B于11月7日斥资607.13万港元回购30.42万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582898108","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582898108?lang=zh_cn&edition=fundamental","pubTime":"2025-11-09 11:17","pubTimestamp":1762658220,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　荃信生物-B（02509）发布公告，于2025年11月7日斥资607.13万港元回购30.42万股。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-11-09/doc-infwunpw8901152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2581188155","title":"荃信生物-B(02509.HK)11月7日耗资607.1万港元回购30.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581188155","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581188155?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 22:37","pubTimestamp":1762526222,"startTime":"0","endTime":"0","summary":"格隆汇11月7日丨荃信生物-B(02509.HK)公告，11月7日耗资607.1万港元回购30.4万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251107/31777867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2581099087","title":"荃信生物-B(02509)11月6日斥资199.61万港元回购8.92万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581099087","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581099087?lang=zh_cn&edition=fundamental","pubTime":"2025-11-06 22:06","pubTimestamp":1762438003,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，于2025年11月6日斥资199.61万港元回购8.92万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2581605773","title":"药闻医讯 | 国家药监局药审中心关于发布《创新药研发中涉及适老化设计时的一般原则及考虑要点（试行）》的通告（2025年第45号）","url":"https://stock-news.laohu8.com/highlight/detail?id=2581605773","media":"百诚医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581605773?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 17:00","pubTimestamp":1762333206,"startTime":"0","endTime":"0","summary":"国家药监局药审中心关于发布《创新药研发中涉及适老化设计时的一般原则及考虑要点（试行）》的通告；10亿美元！根据《国家药监局综合司关于印发药品技术指导原则发布程序的通知》要求，经国家药品监督管理局审查同意，予以发布，自发布之日起施行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105204305a48aa44a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105204305a48aa44a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02157","06978","BK1574","02509"],"gpt_icon":0},{"id":"2581714752","title":"巨头重金入场","url":"https://stock-news.laohu8.com/highlight/detail?id=2581714752","media":"药视声Medispace","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581714752?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 13:19","pubTimestamp":1762319982,"startTime":"0","endTime":"0","summary":"随着肿瘤和自免领域同质化竞争日益严重，巨头们正在寻找新的增长蓝海。中国COPD患者人数已超过1亿，50岁及以上人群患病率高达23.6%，每年死亡人数超100万人，慢阻肺已成为国人的第三大死因。全球范围内，COPD患者数量约3.842亿，中国市场患者数量占全球总数的四分之一以上。这一差距同时也预示着巨大的市场潜力。重金押注COPD跨国药企一掷千金背后，有着深思熟虑的战略考量。对中国药企而言，COPD领域的创新突破是一个重要的国际化机遇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105132657a489a436&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105132657a489a436&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02162","06955","BK1161","02509"],"gpt_icon":0},{"id":"2581832708","title":"荃信生物-B盘中异动 早盘快速下挫5.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581832708","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581832708?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 09:35","pubTimestamp":1762306523,"startTime":"0","endTime":"0","summary":"2025年11月05日早盘09时35分，荃信生物-B股票出现波动，股价大幅跳水5.66%。截至发稿，该股报22.000港元/股，成交量9600股，换手率0.00%，振幅4.29%。荃信生物-B股票所在的生物技术行业中，整体跌幅为0.68%。其相关个股中，维升药业-B、药捷安康-B、中生北控生物科技涨幅较大，振幅较大的相关个股有复宏汉霖、永泰生物-B、药捷安康-B，振幅分别为10.67%、8.29%、8.29%。荃信生物-B公司简介：江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110509352394efbdc4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110509352394efbdc4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2580903263","title":"港股异动 | 荃信生物-B(02509)盘中涨超11% 旗下QX031N授权罗氏 机构称本次交易具备一定稀缺性","url":"https://stock-news.laohu8.com/highlight/detail?id=2580903263","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580903263?lang=zh_cn&edition=fundamental","pubTime":"2025-11-03 14:24","pubTimestamp":1762151061,"startTime":"0","endTime":"0","summary":"消息面上，10月28日，荃信生物宣布与罗氏就其自主研发的长效自免双抗QX031N达成全球独家合作与许可协议。根据协议，罗氏将被授予研究、开发、注册、生产及商业化QX031N的全球独家权益。据悉，QX031N注射液是一款同时靶向TSLP和IL-33的长效双抗。从BD金额和合作方来看，本次交易具备一定稀缺性，QX031N临床价值并不逊色于IBD领域的TL1A双抗，同时亦意味着该靶点组合在全球中具备领先身位和市场潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":105,"code":"91000000","status":"200"}]}}